UHC – Medicare Advantage – Molecular Pathology Policy, Professional and Facility

January 6, 2022

Effective Date February 1st, 2022

Revision of the Overview section with additional details regarding the MolDX Program.

Updated the Reimbursement Guidelines section with additional details relative to obtaining and reporting unique identifiers for molecular diagnostic tests.
Added Definitions and Questions and Answer sections.

Source: https://www.uhcprovider.com/content/dam/provider/docs/public/policies/medadv-reimbursement/rpub/UHC-MEDADV-RPUB-JAN-2022.pdf